2018
A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t)
Lin T, Wieduwilt M, Newell L, Schiller G, Rubenstein S, Stock W, Warlick E, Bixby D, Podoltsev N, An Q, Faderl S, Louie A, Uy G. A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t). Clinical Lymphoma Myeloma & Leukemia 2018, 18: s208. DOI: 10.1016/j.clml.2018.07.063.Peer-Reviewed Original Research311 Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7 + 3 Cytarabine and Daunorubicin
Lin T, Uy G, Wieduwilt M, Newell L, Stuart R, Medeiros B, Schiller G, Rubenstein S, Stock W, Warlick E, Foster M, Bixby D, Podoltsev N, An Q, Faderl S, Louie A, Lancet J. 311 Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7 + 3 Cytarabine and Daunorubicin. Transplantation And Cellular Therapy 2018, 24: s228-s229. DOI: 10.1016/j.bbmt.2017.12.209.Peer-Reviewed Original Research
2017
Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
Medeiros B, Hogge D, Newell L, Bixby D, Solomon S, Strickland S, Lin T, Erba H, Powell B, Podoltsev N, Ryan R, Chiarella M, Louie A, Lancet J. Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2017, 17: s286. DOI: 10.1016/j.clml.2017.07.071.Peer-Reviewed Original ResearchGuadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. The Lancet Oncology 2017, 18: 1317-1326. PMID: 28844816, PMCID: PMC5925750, DOI: 10.1016/s1470-2045(17)30576-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAzacitidineDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleHumansInfusions, IntravenousKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaximum Tolerated DoseMiddle AgedNeoplasm InvasivenessNeoplasm StagingPatient SafetyPrognosisProspective StudiesRemission InductionRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsAcute myeloid leukemiaComposite complete responseTreatment-naive patientsTreatment-naive acute myeloid leukaemiaAdverse eventsMyeloid leukemiaComplete responseFebrile neutropeniaIntensive chemotherapyMyelodysplastic syndromeTreatment cyclesCommon serious adverse eventsRefractory acute myeloid leukemiaPhase 2 resultsFrequent grade 3Worse adverse eventsSerious adverse eventsPhase 2 studyPhase 3 studyCohort of patientsPhase 1 studyComplete tumor responseStandard of careNumber of patientsEffective treatment schedule